Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials.

2.50
Hdl Handle:
http://hdl.handle.net/10541/91994
Title:
Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials.
Authors:
Anderson, Heather; Palmer, Michael K
Abstract:
When assessing the value of a particular treatment, it is important to consider the impact it may have on the quality of life of those being treated. This is particularly so for cancer patients, whose life expectancy may be short. Patients with advanced colorectal cancer who participated in two international comparative studies of raltitrexed ('Tomudex') vs standard 5-fluorouracil (5-FU) plus leucovorin (LV) completed previously validated quality-of-life questionnaires (EORTC questionnaire, EuroQol and Rotterdam Symptom Check List) at various times during the studies. Early statistically significant advantages of raltitrexed vs 5-FU plus LV on quality of life were observed at week 2 in five of eight of the EuroQol and three of four of the Rotterdam Symptom Check List dimensions. Such advantages were not observed using the EORTC questionnaire, which was not completed until week 12. The necessary dose delays and different dose schedules made it difficult in these studies to compare the impact on quality of life of the two treatments. It may be that performance status, effect on disease-related symptoms and the incidence of toxicity are the most important indications of a patient's quality of life.
Affiliation:
Christie Hospital, Withington, Manchester, UK.
Citation:
Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. 1998, 77 Suppl 2:9-14 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
1998
URI:
http://hdl.handle.net/10541/91994
PubMed ID:
9579850
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorPalmer, Michael Ken
dc.date.accessioned2010-02-12T12:30:07Z-
dc.date.available2010-02-12T12:30:07Z-
dc.date.issued1998-
dc.identifier.citationMeasuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. 1998, 77 Suppl 2:9-14 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid9579850-
dc.identifier.urihttp://hdl.handle.net/10541/91994-
dc.description.abstractWhen assessing the value of a particular treatment, it is important to consider the impact it may have on the quality of life of those being treated. This is particularly so for cancer patients, whose life expectancy may be short. Patients with advanced colorectal cancer who participated in two international comparative studies of raltitrexed ('Tomudex') vs standard 5-fluorouracil (5-FU) plus leucovorin (LV) completed previously validated quality-of-life questionnaires (EORTC questionnaire, EuroQol and Rotterdam Symptom Check List) at various times during the studies. Early statistically significant advantages of raltitrexed vs 5-FU plus LV on quality of life were observed at week 2 in five of eight of the EuroQol and three of four of the Rotterdam Symptom Check List dimensions. Such advantages were not observed using the EORTC questionnaire, which was not completed until week 12. The necessary dose delays and different dose schedules made it difficult in these studies to compare the impact on quality of life of the two treatments. It may be that performance status, effect on disease-related symptoms and the incidence of toxicity are the most important indications of a patient's quality of life.en
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subject.meshAnalysis of Variance-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshEnzyme Inhibitors-
dc.subject.meshFluorouracil-
dc.subject.meshHumans-
dc.subject.meshLeucovorin-
dc.subject.meshQuality of Life-
dc.subject.meshQuestionnaires-
dc.subject.meshQuinazolines-
dc.subject.meshThiophenes-
dc.subject.meshThymidylate Synthase-
dc.titleMeasuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.